Structural Basis for Understanding Oncogenic P53 Mutations and Designing Rescue Drugs.Joerger, A.C., Ang, H.C., Fersht, A.R.
(2006) Proc.Natl.Acad.Sci.USA 103: 15056
- PubMed: 17015838
- DOI: 10.1073/pnas.0607286103
- Primary Citation of Related Structures:
- Also Cited By: 3ZME, 4AGQ, 4AGP, 4AGO, 4AGN, 4AGM, 4AGL, 2X0W, 2X0V, 2X0U, 2VUK
- PubMed Abstract:
- Crystal Structure of a Superstable Mutant of Human P53 Core Domain. Insights Into the Mechanism of Rescuing Oncogenic Mutations.
Joerger, A.C.,Allen, M.D.,Fersht, A.R.
(2004) J.Biol.Chem. 279: 1291
- Structures of P53 Cancer Mutants and Mechanism of Rescue by Second-Site Suppressor Mutations.
Joerger, A.C.,Ang, H.C.,Veprintsev, D.B.,Blair, C.M.,Fersht, A.R.
(2005) J.Biol.Chem. 280: 16030
The DNA-binding domain of the tumor suppressor p53 is inactivated by mutation in approximately 50% of human cancers. We have solved high-resolution crystal structures of several oncogenic mutants to investigate the structural basis of inactivation an ...
The DNA-binding domain of the tumor suppressor p53 is inactivated by mutation in approximately 50% of human cancers. We have solved high-resolution crystal structures of several oncogenic mutants to investigate the structural basis of inactivation and provide information for designing drugs that may rescue inactivated mutants. We found a variety of structural consequences upon mutation: (i) the removal of an essential contact with DNA, (ii) creation of large, water-accessible crevices or hydrophobic internal cavities with no other structural changes but with a large loss of thermodynamic stability, (iii) distortion of the DNA-binding surface, and (iv) alterations to surfaces not directly involved in DNA binding but involved in domain-domain interactions on binding as a tetramer. These findings explain differences in functional properties and associated phenotypes (e.g., temperature sensitivity). Some mutants have the potential of being rescued by a generic stabilizing drug. In addition, a mutation-induced crevice is a potential target site for a mutant-selective stabilizing drug.
Cambridge University Chemical Laboratory and Cambridge Centre for Protein Engineering, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, United Kingdom.